Heart failure & cardiomyopathiesCohort study
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
- Retrospective cohort study
- propensity-score matched
- TriNetX research network
Authors' conclusion
SGLT2 inhibitor use is associated with improved outcomes in patients with CTRCD/HF.
Study context
- Population
- Adults with T2DM and cancer exposed to potentially cardiotoxic antineoplastic therapy, with subsequent cardiomyopathy or heart failure (HF) (cancer therapy-related cardiac dysfunction (CTRCD)/HF), 2013–2020; ischemic heart disease excludedmatched cohort
- Participants
- 1,280 adults
- Exposure
- SGLT2 inhibitors vs No SGLT2 inhibitor
- SGLT2 inhibitorsn = 640
- No SGLT2 inhibitorn = 640reference
Main finding
As reported in the abstract
Acute HF exacerbation and all-cause mortality · 2-year follow-up
SGLT2 inhibitors vs No SGLT2 inhibitorOdds ratio (95% CI)P value
acute HF exacerbation
0.483(0.36–0.65)
P < 0.001all-cause mortality
0.296(0.22–0.40)
P = 0.001Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| All-cause hospitalizations or ED visits, AF/flutter, AKI, renal replacement therapy · 2-year follow-up — SGLT2 inhibitors vs No SGLT2 inhibitor · all-cause hospitalizations or ED visits | 0.479 (0.383–0.599) | P < 0.001 | |
| All-cause hospitalizations or ED visits, AF/flutter, AKI, renal replacement therapy · 2-year follow-up — SGLT2 inhibitors vs No SGLT2 inhibitor · AF/flutter | 0.397 (0.213–0.737) | P = 0.003 | |
| All-cause hospitalizations or ED visits, AF/flutter, AKI, renal replacement therapy · 2-year follow-up — SGLT2 inhibitors vs No SGLT2 inhibitor · AKI | 0.486 (0.382–0.619) | P < 0.001 | |
| All-cause hospitalizations or ED visits, AF/flutter, AKI, renal replacement therapy · 2-year follow-up — SGLT2 inhibitors vs No SGLT2 inhibitor · renal replacement therapy | 0.398 (0.189–0.839) | P = 0.012 | |
| 0.20.5125Odds ratio (log scale) |
Original publication
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Fail. Published 25 October 2023. doi:10.1016/j.jchf.2023.08.026
Summarised from the published abstract; every number is checked against it